Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | CCR2 | P41597 | 13/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306095 | 1.00 | CYP2C9 (0.63) | CYP2C9CCR2CYP3A4ALDH1A1LMNA | |
| SCHEMBL306073 | 0.88 | CYP2C9 (0.62) | CYP2C9CCR2CYP3A4TSHR | |
| SCHEMBL305754 | 0.87 | CYP2C9 (0.66) | CYP2C9CCR2CYP3A4TSHR | |
| SCHEMBL306452 | 0.87 | CYP2C9 (0.61) | CYP2C9CCR2CYP3A4TSHR | |
| SCHEMBL307531 | 0.87 | CYP2C9 (0.63) | CYP2C9CCR2CYP3A4TSHR | |
| SCHEMBL306174 | 0.87 | CYP2C9 (0.65) | CYP2C9CCR2CYP3A4TSHR | |
| SCHEMBL12593862 | 0.86 | CYP2C9 (0.62) | CYP2C9CCR2CYP3A4TSHR | |
| SCHEMBL4774906 | 0.86 | KMT2A (0.53) | CYP2C9CCR2ALDH1A1TSHRMEN1 | |
| SCHEMBL12594346 | 0.85 | MEN1 (0.52) | CYP2C9CCR2CYP3A4LMNAGRM4 | |
| SCHEMBL306540 | 0.85 | CYP2C9 (0.61) | CYP2C9CCR2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CYP2C9 192/4885CCR2 1/4885CYP3A4 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.